Primary membranous nephropathy with extremely high levels of CA-125

  • Özant Helvacı Department of Nephrology, Yenimahalle Research and Training Hospital, Yıldırım Beyazit University, Ankara, Turkey
  • Gül Yavuz Department of Internal Medicine, Bozkır State Hospital, Ankara, Turkey
  • İpek Işık Gönül Department of Pathology Gazi University, Ankara, Turkey
  • Yasemin Erten Department of Nephrology Gazi University, Ankara, Turkey
Keywords: membranous nephropathy; membranous glomerulopathy; phospholipaseA2 receptor antibodies; anti-PLA2R; malignancy; carbohydrate antigen; cancer

Abstract

Membranous nephropathy is a glomerular disease that causes nephrotic syndrome. Absent phospholipase A2 receptor antibodies and absent staining with IgG4 may be linked to malignancy-associated MN. Here we present a case that defies that suggestion.
A 42-year-old female presented with anasarca. Kidney biopsy revealed membranous nephropathy, stained positive for IgG but negative for IgG4. Absent phospholipase A2 receptor antibodies was negative. Abdominal tomography revealed a partial thrombosis of the left ovarian vein which raised suspicion for ovarian cancer. Even though her ovaries did not uptake FDG on PET scan, a carbohydrate antigen-125 was ordered. She had extremely high levels of carbohydrate antigen-125 which was unexpected in the course of benign events.
Thorax CT, endoscopy, colonoscopy, mammography, and positron emission tomography were clear in terms of malignancy. Samples from both pleural effusion and ascites were consistent with transudate. Tuberculosis tests were negative. Cytology samples were negative for malign cells. Exploratory surgery was planned but rejected by the patient.
She was treated as primary disease with cyclosporine and methylprednisolone. Rituximab was off-limits due to insurance rules. She had prompt and excellent response. Steroids were tapered and stopped at sixth month and cyclosporine at twelfth month. In her 36 months of drug-free follow up there has been no disease recurrence or a sign of cancer.
Even when all odds are towards malignancy-associated membranous nephropathy, primary disease is still a possibility. We need better markers for malignancy-associated membranous nephropathy. A very high level of CA-125 does not necessarily mean cancer.

References

1) Cattran D, Brenchley P. Membranous nephropathy: thinking through the therapeutic options. Nephrol Dial Transplant. 2017;32(suppl 1):i22-i29.

2) De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421-30.

3) Qu Z, Liu G, Li J, Wu LH, Tan Y, Zheng X, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant. 2012;27(5):1931-7.

4) Kidney Disease: Improving Global Outcomes (KDIGO), Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274.

5) Murtas C, Ghiggeri GM. Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms. J Nephrol. 2016;29(4):469-78.

6) Bomback AS, Fervenza FC. Membranous nephropathy: approaches to treatment. Am J Nephrol. 2018;47(Suppl 1):30-42.

7) Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997.

8) Ren S, Wu C, Zhang Y, Wang AY, Li G, Wang L, Hong D. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306-13.

9) Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566-74.

10) Sinico RA, Mezzina N, Trezzi B, Ghiggeri GM, Radice A. Immunology of
membranous nephropathy: from animal models to humans. Clin Exp Immunol. 2016;183(2):157-65.

11) Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58(3):308-12.

12) Sikaris KA. CA125--a test with a change of heart. Heart Lung Circ. 2011;20(10):634-40.

13) Altun B, Erdem Y, Oymak O, Yasavul U, Turgan C, Cağlar S. A case of membranous glomerulonephritis with elevated serum level of CA-125. Clin Nephrol. 1995;44(4):277-8.

14) Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36-46.
Published
2020-08-12
How to Cite
1.
Helvacı Özant, Yavuz G, Gönül İpek I, Erten Y. Primary membranous nephropathy with extremely high levels of CA-125. Rev Nefrol Dial Traspl. [Internet]. 2020Aug.12 [cited 2024Dec.29];39(4):266-70. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/497
Section
Case Report